Qiagen

Evonetix Appoints Colin McCracken as Chief Executive Officer

Retrieved on: 
Monday, June 13, 2022
Semiconductor, Health, Technology, Genetics, Research, Science, Biotechnology, Company, Research, CEO, Life Technologies, LTD, Qiagen, Gene, Â, Technology, DNA, Thermo Fisher Scientific, Board, Chair, General manager, Synthetic biology, Management

EVONETIX LTD (Evonetix), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect.

Key Points: 
  • EVONETIX LTD (Evonetix), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect.
  • Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Companys global reach.
  • Colin McCracken, Chief Executive Officer at Evonetix, commented: The team at Evonetix has achieved major milestones in building the technology to enable semiconductor based decentralised DNA synthesis.
  • He will resume his role as Chief Technology Officer with the Company following a transition to Colin."

Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsay Edwards as CTO

Retrieved on: 
Thursday, June 9, 2022
Software, Research, Internet, Pharmaceutical, Hardware, Data Management, Technology, Genetics, Science, Nanotechnology, Biotechnology, Health, Francis Crick Institute, Associate, COO, QGEN, Therapy, University of Oxford, Machine learning, Khosla Ventures, Technology, AstraZeneca, NYSE, ABC, Eric, Artificial intelligence, CEO, Pathology, Centauri, Capital, Genetics, Thermo Fisher Scientific, NVIDIA, DeepMind, Bone, Human, Machine, Broad Institute, Biology, Montreal Institute for Genocide and Human Rights Studies, Algorithm, Immunology, Patient, Single-cell analysis, Artificiality, Leadership, LSE, SVP, Disease, Gene, MIT, Twitter, Drug discovery, Genomics, Protein, Pharmaceutical industry, Medical device, Cryptocurrency, Management, Platform, Qiagen, Relation, Abcam, Pfizer

Dr. David Roblin joins the company as Chief Executive Officer and Dr. Lindsay Edwards as Chief Technology Officer and President of Platform.

Key Points: 
  • Dr. David Roblin joins the company as Chief Executive Officer and Dr. Lindsay Edwards as Chief Technology Officer and President of Platform.
  • Our approach brings together, for the first time, human genetics, single-cell omics, functional genomics, and active-graph machine learning in a single, engineered design.
  • With active-graph machine learning, Relation can understand the huge number of combinatorial functional relationships between genes, proteins, and drugs.
  • Roblin has been involved in Relation since its founding, while engaged as CEO of Juvenescence Therapeutics, an early investor in Relation.

Single Cell Genomics in NGS Market Reaches $780M says Kalorama Information

Retrieved on: 
Thursday, May 12, 2022
DNA, Software, NGS, Gene, Analysis, Microscopy, Qiagen, Method, Research, Industry, Biotechnology, RNA, Genomics, Bio-Rad Laboratories, Fine chemical, Illumina, Science, Fluidigm

ARLINGTON, Va., May 12, 2022 /PRNewswire-PRWeb/ -- The total market for single cell genomics using sequencing is estimated to be $780M in 2021. That includes - the hardware, service of the hardware, software, and consumables including for the sequencing step and other types of downstream analysis. That's the finding of Single Cell Analysis in Next-Generation Sequencing Markets (Market Size and Forecast, Segment Breakouts), 2022-2027 from Kalorama Information.

Key Points: 
  • ARLINGTON, Va., May 12, 2022 /PRNewswire-PRWeb/ -- The total market for single cell genomics using sequencing is estimated to be $780M in 2021.
  • That's the finding of Single Cell Analysis in Next-Generation Sequencing Markets (Market Size and Forecast, Segment Breakouts), 2022-2027 from Kalorama Information.
  • Single Cell Analysis in Next-Generation Sequencing Markets (Market Size and Forecast, Segment Breakouts), 2022-2027 focuses on the market for single cell genomics products -- the hardware, service of the hardware, software, and consumables including for the sequencing step and other types of downstream analysis.
  • Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

SkylineDx appoints Fayyaz Memon as President and General Manager USA

Retrieved on: 
Tuesday, April 26, 2022
CEO, Biotechnology, DNA, Dermatology, Research, CA, Leadership, Inflammation, Patient, Qiagen, SAN, Regulatory affairs, Hematology, Thermo Fisher Scientific, Heart, General manager, Disease, Ali-Akbar Fayyaz, Asuragen, Pharmaceutical industry, Medical device, Headquarters

The company is entering a new growth phase of its US business operations and appointed Fayyaz Memon as President and General Manager USA.

Key Points: 
  • The company is entering a new growth phase of its US business operations and appointed Fayyaz Memon as President and General Manager USA.
  • He joins from Natera, global leader in cell-free DNA testing, where he was Vice President of Regulatory Affairs.
  • Fayyaz has previously held a number of senior leadership and management positions, including positions at Qiagen, Asuragen, and Thermo Fisher Scientific.
  • I am excited to join the SkylineDx team to bring SkylineDx's products to patients in an efficient manner through regulatory framework and effective commercialization," concludes Fayyaz Memon.

SkylineDx appoints Fayyaz Memon as President and General Manager USA

Retrieved on: 
Tuesday, April 26, 2022
CEO, Biotechnology, DNA, Dermatology, Research, CA, Leadership, Inflammation, Patient, Qiagen, SAN, Regulatory affairs, Hematology, Thermo Fisher Scientific, Heart, General manager, Disease, Ali-Akbar Fayyaz, Asuragen, Pharmaceutical industry, Medical device, Headquarters

The company is entering a new growth phase of its US business operations and appointed Fayyaz Memon as President and General Manager USA.

Key Points: 
  • The company is entering a new growth phase of its US business operations and appointed Fayyaz Memon as President and General Manager USA.
  • He joins from Natera, global leader in cell-free DNA testing, where he was Vice President of Regulatory Affairs.
  • Fayyaz has previously held a number of senior leadership and management positions, including positions at Qiagen, Asuragen, and Thermo Fisher Scientific.
  • I am excited to join the SkylineDx team to bring SkylineDx's products to patients in an efficient manner through regulatory framework and effective commercialization," concludes Fayyaz Memon.

Global KRAS Inhibitors Market & Clinical Trials Forecast Report to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 22, 2022
Health, Clinical Trials, Cdx, Clinical trial, LabCorp, Indication, AMP, Research, Cancer, Patient, Qiagen, Proteolysis targeting chimera, Cas9, NSCLC, Amgen, Vaccine, SHP2, Sanofi, Colorectal cancer, Large-cell lung carcinoma, Disease, KRAS, Precision medicine, Therapy, Pharmaceutical industry

Among them, Adagrasib is one of the most advanced KRAS inhibitors in phase-III clinical trials while the others are mainly present in phase-I/II clinical trials.

Key Points: 
  • Among them, Adagrasib is one of the most advanced KRAS inhibitors in phase-III clinical trials while the others are mainly present in phase-I/II clinical trials.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, commercial information of already available KRAS inhibitors, and sales forecast till 2028.
  • US To Dominate Global KRAS Inhibitors Market: >50% Market Share
    Number of KRAS Inhibitors In Trials: > 45 Drugs
    12.
  • Global KRAS Inhibitors Clinical Pipeline By Company, Indication & Phase
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005367/en/

OncXerna Therapeutics Highlights the Xerna™ TME Panel’s Prognostic and Predictive Value Across Indications and Therapeutic Classes at the AACR Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Therapy, Biomarker, LinkedIn, TME, PS, DLL4, Patient, Exact sciences, Colorectal cancer, Tumor microenvironment, AACR, American Association, Neoplasm, Precision medicine, RNA, CEO, MSI-H, PPV, Artificial intelligence, Association, American Association for Cancer Research, Biology, VEGF, Twitter, Stomach, Mutation, GLOBE, Melanoma, PD-L1, Data, MSI, Radiation, Pharmaceutical industry, Vaccine, Qiagen, Bavituximab

WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”) is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates. Today the company announced biomarker data demonstrating the Xerna TME Panel’s prognostic value across multiple indications in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting. Data also suggest the potential for Xerna TME Panel to predict patients most likely to benefit from immune- and angiogenic-targeted therapy.

Key Points: 
  • Today the company announced biomarker data demonstrating the Xerna TME Panels prognostic value across multiple indications in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.
  • Data also suggest the potential for Xerna TME Panel to predict patients most likely to benefit from immune- and angiogenic-targeted therapy.
  • RNA expression signatures to predict therapeutic response have struggled with defining thresholds that clearly distinguish patients more likely to benefit from those that are not.
  • "Using artificial intelligence, we have been able to unlock the potential of RNA-based expression gene signatures, said Laura Benjamin, CEO of OncXerna Therapeutics.

Singular Genomics Systems, Inc. Reports Recent Highlights, Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Wednesday, March 2, 2022
Singular, Form 10-K, Genomics, Agilent Technologies, Investment, Science, Investor, Forward-looking statement, Catalog, Risk, Government, KAPA, RNA, DNA, Doctor of Philosophy, Roche, Coronavirus Scientific Advisory Board (Turkey), G4, Technical report, Board of directors, Qiagen, Board, SEC, COVID-19, Medicine, Proteomics, Spatial analysis, EAP, Exact sciences, PX, NGS, F2, OMIC, Technology, Partnership, Federal, Nasdaq, TAP, GLOBE, CRO, Communications satellite, Antibiotics, Fine chemical, Video game, Management, Lithium

Operating expenses for the fourth quarter of 2021 totaled$19.7 million, compared to$7.6 millionfor the fourth quarter of 2020.

Key Points: 
  • Operating expenses for the fourth quarter of 2021 totaled$19.7 million, compared to$7.6 millionfor the fourth quarter of 2020.
  • Net loss for the fourth quarter of 2021 was$19.8 million, or $0.27 per common share, compared to$7.9 million,or $0.73 per common share, for the fourth quarter of 2020.
  • Net loss for 2021 was$98.8 million, or $2.10 per common share, compared to$27.9 million,or $2.64 per common share, in 2020.
  • Singular Genomics management team will host a conference call today, March 2, 2022, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

New Study from StrategyR Highlights a $1.2 Billion Global Market for Next Generation Sequencing (NGS) Data Analysis by 2026

Retrieved on: 
Tuesday, February 22, 2022
Cloud, Cloud computing, Data analysis, Globe, RNA, Awareness, Intelligence, COVID-19, Eurofins Scientific, Research, Forecasting, Agilent Technologies, Solution, Sophia Genetics, Growth, Adoption, Illumina, Inc., Breast, NGS, SAN, CAGR, Service, Wellcome Sanger Institute, Prevalence, Diagnosis, Players, Pacific Biosciences, Hospital, DNA, GIA, Automation, Software, Algorithm, Method, Internet, DNA sequencing, Clifton Springs Hospital & Clinic, Methylation, Geography, Clinical research, Marketing, Technology, Thermo Fisher Scientific, DNAnexus, Data lake, Renewable energy, Pharmaceutical industry, Medical imaging, Others, Workflow, Qiagen, Illumina

SAN FRANCISCO, Feb. 22, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Feb. 22, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics" .
  • NGS data analysis encompasses primary, secondary and tertiary analysis steps, with some of these stages holding potential for automation through new sequencing solutions.
  • This segment currently accounts for a 44% share of the global Next Generation Sequencing (NGS) Data Analysis market.
  • Companies lacking the necessary infrastructure for data analysis, interpretation, and management are increasingly adopting cost-effective NGS data analysis services.

SciNote Joins the Tetra Partner Network to Meet Customer Demand for Increased Efficiency in Discovery

Retrieved on: 
Wednesday, February 16, 2022
Cloud, Tetra, AI, CEO, ELN, API, Food and Drug Administration, Data science, Science, Government, Title 21 CFR Part 11, VP, Movement, Cros, R, Efficiency, Business development, GxP, Qiagen, Safety, ISO, Therapy, Electronic lab notebook, Compliance, University of Washington Information School, Foundation for the National Institutes of Health, National, FDA, View, SOP, NIH, TDP, Data management, Research, Multimedia, University, CFR, Life, Medical device, Fine chemical, Discovery, Industry

BOSTON, Feb. 16, 2022 /PRNewswire/ -- TetraScience , the R&D Data Cloud company, announced today that SciNote , maker of a powerful Electronic Lab Notebook (ELN), has joined the Tetra Partner Network to meet customer demand for greater efficiency in Discovery workflows and data management.

Key Points: 
  • BOSTON, Feb. 16, 2022 /PRNewswire/ -- TetraScience , the R&D Data Cloud company, announced today that SciNote , maker of a powerful Electronic Lab Notebook (ELN), has joined the Tetra Partner Network to meet customer demand for greater efficiency in Discovery workflows and data management.
  • We welcome the opportunity to partner with them so that customers can focus on science rather than data formatting."
  • As a Tetra Partner, SciNote accelerates access to, and increases the value of, scientific data through the Tetra Data Platform (TDP) the industry's only R&D focused, vendor-agnostic, and cloud-native platform.
  • To accompany the software solution, SciNote provides best rated customer support and implementation consultancy to all clients.